An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2009 |
| End Date: | December 2013 |
| Contact: | Please reference Study ID Number: MV22255 |
| Email: | genentechclinicaltrials@druginfo.com |
| Phone: | 888-662-6728 (U.S. Only) |
Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin
This observational study will assess factors leading to dose reductions/treatment
discontinuations and the effect on sustained virological response in patients with chronic
hepatitis C receiving a long-acting interferon (e.g. Pegasys/peginterferon alfa-2a) and
ribavirin. Data will be collected from each patient for the duration of their treatment and
for up to 6 months thereafter.
We found this trial at
1
site
Click here to add this to my saved trials
